A detailed history of Morgan Stanley transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 93,266 shares of TRDA stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,266
Previous 49,051 90.14%
Holding current value
$1.65 Million
Previous $698,000 113.61%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.65 - $17.86 $603,534 - $789,679
44,215 Added 90.14%
93,266 $1.49 Million
Q2 2024

Oct 17, 2024

SELL
$11.85 - $16.45 $693,355 - $962,505
-58,511 Reduced 54.4%
49,051 $698,000
Q2 2024

Aug 14, 2024

SELL
$11.85 - $16.45 $693,355 - $962,505
-58,511 Reduced 54.4%
49,051 $698,000
Q1 2024

Oct 17, 2024

BUY
$11.58 - $17.0 $677,557 - $994,687
58,511 Added 119.29%
107,562 $1.52 Million
Q1 2024

Aug 16, 2024

BUY
$11.58 - $17.0 $674,627 - $990,386
58,258 Added 118.16%
107,562 $1.52 Million
Q1 2024

May 15, 2024

BUY
$11.58 - $17.0 $674,627 - $990,386
58,258 Added 118.16%
107,562 $1.52 Million
Q4 2023

Aug 16, 2024

BUY
$11.36 - $16.99 $2,874 - $4,298
253 Added 0.52%
49,304 $743,000
Q4 2023

Feb 13, 2024

BUY
$11.36 - $16.99 $322,146 - $481,802
28,358 Added 135.39%
49,304 $743,000
Q3 2023

Nov 15, 2023

SELL
$13.61 - $18.01 $121,904 - $161,315
-8,957 Reduced 29.95%
20,946 $330,000
Q2 2023

Aug 14, 2023

SELL
$11.02 - $18.01 $130,752 - $213,688
-11,865 Reduced 28.41%
29,903 $452,000
Q1 2023

May 15, 2023

BUY
$9.58 - $16.2 $161,729 - $273,488
16,882 Added 67.84%
41,768 $605,000
Q4 2022

Feb 14, 2023

BUY
$13.52 - $22.89 $194,093 - $328,608
14,356 Added 136.33%
24,886 $336,000
Q3 2022

Nov 14, 2022

SELL
$9.65 - $15.76 $102,820 - $167,922
-10,655 Reduced 50.3%
10,530 $166,000
Q2 2022

Oct 27, 2022

BUY
$5.49 - $12.94 $70,403 - $165,942
12,824 Added 153.38%
21,185 $258,000
Q2 2022

Aug 15, 2022

BUY
$5.49 - $12.94 $70,403 - $165,942
12,824 Added 153.38%
21,185 $258,000
Q1 2022

Oct 27, 2022

SELL
$7.99 - $16.93 $102,463 - $217,110
-12,824 Reduced 60.53%
8,361 $78,000
Q1 2022

May 13, 2022

BUY
$7.99 - $16.93 $33,550 - $71,089
4,199 Added 100.89%
8,361 $78,000
Q4 2021

Feb 14, 2022

BUY
$13.7 - $35.0 $57,019 - $145,670
4,162 New
4,162 $71,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $556M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.